Well, at this point, I don’t think patients should be selected. And I think the data we reported last year at the Congress and this year at the Congress show that in an unselected patient population, when you use Temab-A in combination with Bevacizumab, that there’s benefit in PFS and OS and response rates compared to the historical controls with FOLFOX plus Bevacizumab...
Well, at this point, I don’t think patients should be selected. And I think the data we reported last year at the Congress and this year at the Congress show that in an unselected patient population, when you use Temab-A in combination with Bevacizumab, that there’s benefit in PFS and OS and response rates compared to the historical controls with FOLFOX plus Bevacizumab. So there’s an ongoing phase three study now, the AndromMETa-560, which is evaluating Temab-A, 2.4 mg per kg plus Bev, the regimen I presented today, versus FOLFOX plus Bevacizumab in an unselected patient population. These results will be stratified by c-MET expression. The trial will enroll more than 900 patients. So we will be able to look at the different levels of c-MET expression and how that correlates with efficacy. But at this time, I think the logical step forward is future enrollment in this trial in an unselected patient population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.